水浒传游戏机下载

Dr. Guo Feng has been responsible for the overall management, business and strategy of Genor Biopharma since April 2020 as Chief Executive Officer, Executive Director of the Board. And he has been appointed Chairman of the Board in November 2021.

Dr. Guo has more than 20 years’ experience in the biopharmaceutical industry.

Prior to joining Genor Biopharma, Dr. Guo worked at Merck as VP and Head of Merck China R&D Hub; at Pfizer as Head of Pfizer (Wuhan) Research and Development Centre; and at Xuanzhu (Beijing) Pharmaceutical Technology Ltd as Chairman of the board.

Dr. Guo obtained a Ph.D. in clinical pharmacology from the University of Toronto in Canada.

25+ years of academic research and drug discovery experience, especially in the fields of oncology, immune-oncology, inflammation and autoimmune diseases.

Previously worked at Shanghai WuXi AppTec as Vice President of drug discovery and at Baylor College of Medicine as tenured professor of immunology and pathology.

Rich experience and insights in the biopharmaceutical industry in China and the United States.

Previously worked at leading U.S. biotech companies including Amgen, as Scientific Director of CMC.

Visiting professor of Peking University since 2007.

Former senior director and head of the clinical development department at Janssen, prior to which also worked at Merck and Pfizer

Over 20 years of experience in biopharmaceutical industry, focusing on sales and marketing in China.

Previously worked at Roche China as Vice President, Astra Zeneca as Senior Vice President, and Pfizer as Senior Sales Director.

An outstanding expert in biologics development, production and management.

30 years of experience in the operation and management in the CMC and production departments of internationally renowned biopharmaceutical companies such as Genentech Inc., Bayer Corporation and Progenics Pharmaceuticals.

Led the establishment and operation of 3 Chinese biopharmaceutical companies, including Wuxi AppTec, MabPlex International and CMAB Biopharma Inc.

25+ years of experience in business development, alliance and portfolio management and drug discovery and development.

Previously worked at Abgenix (acquired by Amgen), Seattle Genetics (now Seagen), MacroGenics and several biopharma companies in the US as CBO/Head of BD.

Led a number of strategic, and award winning, cooperation projects with considerable influence in the industry.

Over 20 years regulatory affairs experience in multiple leading big pharma and biopharma companies, with excellent insight of China and global regulatory landscape.

The former Head of Regulatory Affairs of China & HK region in AbbVie, headed the regulatory strategy development and regulatory activities and led a number of CTA and NDA applications and approvals.